Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

Corporate Breaking News

Home : Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine

Dec 14 2022	Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent...


Source:https://www.prnewswire.com:443/news-releases/superior-results-of-the-comparative-study-of-the-companys-recombinant-two-component-covid-19-vaccine-recov-as-compared-to-international-mainstream-mrna-vaccine-301702595.html

Related News
» Dr. Jackie Glenn, Corporate Culture Strategist, Joins SmartBear Board of Directors » TECNO Unveils the First Flagship Laptop MEGABOOK S1, Breaking the Boundary with High Performance and Lightest Experience